Concord Drugs Ltd — Important, 22-11-2025: Company Update

Concord Drugs has published its consolidated and standalone financial results for the quarter and half-year ended September 30, 2025. For the quarter, consolidated revenue was ₹10.08 Cr (standalone ₹10.28 Cr), with a consolidated profit of ₹0.19 Cr (standalone ₹0.19 Cr). For the half-year, consolidated revenue reached ₹23.46 Cr (standalone ₹23.88 Cr), and consolidated profit was ₹0.31 Cr (standalone ₹0.31 Cr). The Board of Directors approved these results after review by the Audit Committee, offering stakeholders a clear view of recent company performance.